CNBX Pharmaceuticals (CNBX) Stock Overview
A clinical-stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 0/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
+ 2 more risks
CNBX Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
CNBX Pharmaceuticals Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.00045 |
| 52 Week High | US$0.016 |
| 52 Week Low | US$0.0002 |
| Beta | -0.35 |
| 1 Month Change | 50.00% |
| 3 Month Change | 50.00% |
| 1 Year Change | -93.48% |
| 3 Year Change | -99.98% |
| 5 Year Change | -100.00% |
| Change since IPO | -100.00% |
Recent News & Updates
Recent updates
Shareholder Returns
| CNBX | US Pharmaceuticals | US Market | |
|---|---|---|---|
| 7D | 12.5% | 1.3% | 1.2% |
| 1Y | -93.5% | 26.1% | 15.8% |
Return vs Industry: CNBX underperformed the US Pharmaceuticals industry which returned 26% over the past year.
Return vs Market: CNBX underperformed the US Market which returned 15.8% over the past year.
Price Volatility
| CNBX volatility | |
|---|---|
| CNBX Average Weekly Movement | 43.1% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: CNBX's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: CNBX's weekly volatility (43%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2004 | 1 | Eyal Barad | www.cnbxpharma.com |
CNBX Pharmaceuticals Inc., a clinical-stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the local treatment of lateral spreading, or sessile, colorectal polyps during colonoscopy, BRST-33 for the treatment of breast cancer, MLN-33 for the treatment of melanoma, and PRST-33 for the treatment of prostate cancer.
CNBX Pharmaceuticals Inc. Fundamentals Summary
| CNBX fundamental statistics | |
|---|---|
| Market cap | US$301.28k |
| Earnings (TTM) | -US$313.98k |
| Revenue (TTM) | n/a |
Is CNBX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CNBX income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$313.98k |
| Earnings | -US$313.98k |
Last Reported Earnings
Aug 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.00042 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | -48.0% |
How did CNBX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/12/26 16:16 |
| End of Day Share Price | 2025/12/26 00:00 |
| Earnings | 2025/08/31 |
| Annual Earnings | 2025/08/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
CNBX Pharmaceuticals Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.